RAPP Q2 2025 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

RAPPRapport Therapeutics, Inc. Common Stock

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$29M

Net Income

-$27M

EPS (Diluted)

$-0.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$285M

Total Liabilities

$22M

Stockholders' Equity

$264M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$208,000	+100.0%
Operating Income	-$29M	-$21M	-41.8%
Net Income	-$27M	-$18M	-47.5%